1-[3-(4-Methyl-piperazin-1-yl)-propyl]-3-(5-thiophen-3-yl-pyridin-3-yl)-1H-indole

ID: ALA327721

Chembl Id: CHEMBL327721

PubChem CID: 5329366

Max Phase: Preclinical

Molecular Formula: C25H28N4S

Molecular Weight: 416.59

Molecule Type: Small molecule

Associated Items:

Names and Identifiers

Canonical SMILES:  CN1CCN(CCCn2cc(-c3cncc(-c4ccsc4)c3)c3ccccc32)CC1

Standard InChI:  InChI=1S/C25H28N4S/c1-27-10-12-28(13-11-27)8-4-9-29-18-24(23-5-2-3-6-25(23)29)22-15-21(16-26-17-22)20-7-14-30-19-20/h2-3,5-7,14-19H,4,8-13H2,1H3

Standard InChI Key:  FYOYABXHBTZQMB-UHFFFAOYSA-N

Alternative Forms

Associated Targets(Human)

KDR Tclin Vascular endothelial growth factor receptor 2 (20924 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
PDGFRB Tclin VEGF-receptor 2 and PDGF-receptor beta (KDR and PDGFR beta) (29 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor 1 and 2 (Flt-1 and KDR) (27 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT4 Tclin Vascular endothelial growth factor receptor 2 and 3 (KDR and Flt-4) (23 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 1 (50 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
KDR Tclin VEGF-receptor 2 and Fibroblast growth factor receptor 2 (15 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
SRC Tclin VEGF-receptor 2 and tyrosine-protein kinase SRC (25 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
FLT1 Tclin Vascular endothelial growth factor receptor (287 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Associated Targets(non-human)

Rattus norvegicus (775804 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 416.59Molecular Weight (Monoisotopic): 416.2035AlogP: 5.07#Rotatable Bonds: 6
Polar Surface Area: 24.30Molecular Species: BASEHBA: 5HBD:
#RO5 Violations: 1HBA (Lipinski): 4HBD (Lipinski): #RO5 Violations (Lipinski): 1
CX Acidic pKa: CX Basic pKa: 8.71CX LogP: 4.08CX LogD: 2.75
Aromatic Rings: 4Heavy Atoms: 30QED Weighted: 0.44Np Likeness Score: -1.82

References

1. Fraley ME, Arrington KL, Hambaugh SR, Hoffman WF, Cunningham AM, Young MB, Hungate RW, Tebben AJ, Rutledge RZ, Kendall RL, Huckle WR, McFall RC, Coll KE, Thomas KA..  (2003)  Discovery and evaluation of 3-(5-thien-3-ylpyridin-3-yl)-1H-indoles as a novel class of KDR kinase inhibitors.,  13  (18): [PMID:12941314] [10.1016/s0960-894x(03)00627-9]
2. Jacquemard U, Dias N, Lansiaux A, Bailly C, Logé C, Robert JM, Lozach O, Meijer L, Mérour JY, Routier S..  (2008)  Synthesis of 3,5-bis(2-indolyl)pyridine and 3-[(2-indolyl)-5-phenyl]pyridine derivatives as CDK inhibitors and cytotoxic agents.,  16  (9): [PMID:18439832] [10.1016/j.bmc.2008.03.034]
3. Mondal D, Amin SA, Moinul M, Das K, Jha T, Gayen S..  (2022)  How the structural properties of the indole derivatives are important in kinase targeted drug design?: A case study on tyrosine kinase inhibitors.,  53  [PMID:34864496] [10.1016/j.bmc.2021.116534]

Source